| Pharmaceutical Information |
| Drug Name |
Optimark |
| Drug ID |
BADD_D01621 |
| Description |
Gadoversetamide, marketed under the trade name OptiMARK, is a gadolinium compound used as a contrast agent in magnetic resonance imaging (MRI), particularly imaging of the brain, spine and liver. |
| Indications and Usage |
Gadoversetamide is an MRI contrast agent used for MRI diagnostic procedures to provide increased enhancement and visualization of lesions of the brain, spine and liver, including tumors. |
| Marketing Status |
approved; investigational |
| ATC Code |
V08CA06 |
| DrugBank ID |
DB00538
|
| KEGG ID |
D01646
|
| MeSH ID |
C112666
|
| PubChem ID |
6435809
|
| TTD Drug ID |
D0X0GI
|
| NDC Product Code |
Not Available |
| UNII |
Not Available
|
| Synonyms |
gadoversetamide | OptiMARK |
|
| Chemical Information |
| Molecular Formula |
C20H34GdN5O10 |
| CAS Registry Number |
131069-91-5 |
| SMILES |
COCCNC(=O)CN(CCN(CCN(CC(=O)NCCOC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3] |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
